Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability

Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability

Considering the undesirable metabolic stability of our recently identified NNRTI 5 (t1/2 = 96 min) in human liver microsomes, we directed our efforts to improve its metabolic stability by introducing a new favorable hydroxymethyl side chain to the C-5 position of pyrimidine. This strategy provided a...

Full description

Bibliographic Details
Main Authors:	Ya-Li Sang, Christophe Pannecouque, Erik De Clercq, Shuai Wang, Fen-Er Chen
Format:	Article
Language:	English
Published:	Elsevier 2023-07-01
Series:	Acta Pharmaceutica Sinica B
Subjects:	NNRTI HIV-1 DAPYs Picomolar Metabolic stability
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383523001120

Similar Items

Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability
by: Xin Jin, et al.
Published: (2023-03-01)

Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs
by: Ting-Ting Li, et al.
Published: (2020-03-01)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020-06-01)

Approved HIV reverse transcriptase inhibitors in the past decade
by: Guangdi Li, et al.
Published: (2022-04-01)

Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase
by: Elleder Daniel, et al.
Published: (2012-12-01)

Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Da Feng, et al.
Published: (2022-11-01)

Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility
by: Tomasz Frączek, et al.
Published: (2018-01-01)

Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy
by: Fred S. Sarfo, et al.
Published: (2016-06-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer, et al.
Published: (2013-11-01)

Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies
by: Abhimanyu K. Singh, et al.
Published: (2022-05-01)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
by: Richa Dwivedi, et al.
Published: (2022-07-01)

Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility
by: Li-Min Zhao, et al.
Published: (2023-12-01)

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy
by: Yuan Lei, et al.
Published: (2020-02-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Characterization, Recombinant Production and Structure-Function Analysis of NvCI, A Picomolar Metallocarboxypeptidase Inhibitor from the Marine Snail <i>Nerita versicolor</i>
by: Giovanni Covaleda-Cortés, et al.
Published: (2019-08-01)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
by: Maryam A. Jordaan, et al.
Published: (2020-08-01)

Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study
by: Zhenzhen Zhou, et al.
Published: (2023-01-01)

NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal
by: Benjamin Trinité, et al.
Published: (2019-06-01)

Uranium Isotope (U-232) Removal from Waters by Biochar Fibers: An Adsorption Study in the Sub-Picomolar Concentration Range
by: Maria Philippou, et al.
Published: (2022-10-01)

Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01)

Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
by: Sara Iannuzzi, et al.
Published: (2021-07-01)

Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region
by: Tao Zhang, et al.
Published: (2022-11-01)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
by: Oliver T. Stirrup, et al.
Published: (2019-10-01)

Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions
by: Ming-Tain Lai, et al.
Published: (2016-09-01)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
by: Phasomsap Chayapa, et al.
Published: (2011-10-01)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
by: Shaili Gupta, et al.
Published: (2014-09-01)

The Clinical Potential of Circulating Tumor Cells; The Need to Incorporate a Modern “Immunological Cocktail” in the Assay
by: Jonathan W. Uhr
Published: (2013-12-01)

Small Molecules of Natural Origin as Potential Anti-HIV Agents: A Computational Approach
by: Luminita Crisan, et al.
Published: (2021-07-01)

Development of HIV Drug Resistance in a Cohort of Adults on First-Line Antiretroviral Therapy in Tanzania during the Stavudine Era
by: Raphael Z. Sangeda, et al.
Published: (2021-11-01)

Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model
by: Daniela Zizioli, et al.
Published: (2023-07-01)

Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection
by: Dongwei Kang, et al.
Published: (2022-10-01)

Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential
by: Thomas Rossetti, et al.
Published: (2022-09-01)

Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery
by: Fedora Grande, et al.
Published: (2019-04-01)

Corrigendum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential
by: Thomas Rossetti, et al.
Published: (2023-03-01)

Erratum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential
by: Frontiers Production Office
Published: (2022-11-01)

Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy
by: Eriko Ohsaki, et al.
Published: (2021-08-01)

Coloração de núcleos de esporos e hifas do cogumelo Agaricus blazei Nucleus stain of spores and hifas Ofagaricus blazei
by: Cláudia Regina Gontijo Labory, et al.
Published: (2003-04-01)

FIRST KARYOTYPE REPORT ON Colocasia oresbia: A COMPARATIVE CYTOGENETIC STUDY BETWEEN TWO VARIETIES
by: Begum Kazi N., et al.
Published: (2020-12-01)

Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
by: Kaijun Jin, et al.
Published: (2020-02-01)

Chlortetracycline-Functionalized Silver Nanoparticles as a Colorimetric Probe for Aminoglycosides: Ultrasensitive Determination of Kanamycin and Streptomycin
by: Ganesh Dattatraya Saratale, et al.
Published: (2020-05-01)